The Nomination Committee for the 2023 Annual General Meeting of
- Karl Tobieson, appointed by
Linc Ivo Staijen , appointed byHBM Healthcare Investments - Jan Särlvik, appointed by Fjärde AP-fonden
- Björn Wasing, appointed SEB-Stiftelsen and S-E-Bankens Utvecklingsstiftelse
Wenche Rolfsen , Chairman of the Board (convener)
The Nomination Committee together represents approximately 38 percent of all voting rights in the company as of
Shareholders wishing to submit comments or proposals to the Nomination Committee can send them via email to info@indexpharma.com.
For more information:
Johan Giléus, acting CEO
Phone: +46 8 122 038 50
E-mail: johan.gileus@indexpharma.com
Publication
The information was submitted for publication through the agency of the contact person set out above at
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III study CONCLUDE as a novel treatment of moderate to severe ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
InDex is based in
https://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-holding-ab--publ--announces-nomination-committee-for-the-2023-annual-general-m,c3654504
https://mb.cision.com/Main/9612/3654504/1643290.pdf
(c) 2022 Cision. All rights reserved., source